African Medicines Agency: Kigali Regulatory Hubs Launched to Boost Capacity

• The African Medicines Agency (AMA) launched two regulatory hubs in Kigali, Rwanda, on October 27, during the inaugural AMA Week.
• The AMA Capacity Strengthening Hub will address skill gaps and coordinate training for regulatory professionals across Africa.
• The AMA Regulatory Innovation and Manufacturing Readiness Hub will provide early scientific guidance to manufacturers and innovators to meet regulatory standards.
• These hubs aim to accelerate regulatory decisions, support local manufacturing, and reduce duplication across Africa's 55 national regulatory systems.
• A more coordinated regulatory approach is expected to strengthen Africa's position in negotiations with pharmaceutical suppliers and enhance timely access to medicines.

This proactive engagement involves providing crucial scientific guidance and assisting them in preparing to meet the stringent regulatory requirements for product quality, safety, and efficacy.

The African Medicines Agency (AMA), an initiative of the African Union, has established two pivotal regulatory hubs in Kigali, Rwanda. These new facilities, inaugurated on Tuesday, October 27, during the first-ever AMA Week, are strategically located at the AMA headquarters. Their primary objective is to empower African nations to expedite regulatory decisions concerning medical products and to bolster the capacity of local manufacturers in bringing essential medicines to market across the continent.

These newly launched entities are the AMA Capacity Strengthening Hub and the AMA Regulatory Innovation and Manufacturing Readiness Hub. Together, they represent a significant step towards fostering a more efficient and responsive pharmaceutical landscape in Africa. Delese Mimi Darko, the Director-General of AMA, emphasized that such a system is designed to facilitate scientific collaboration among countries, ensure prompt regulatory judgments, support domestic industry, and enable a unified, swift response to public health imperatives.

The AMA Capacity Strengthening Hub is specifically tasked with identifying critical skill deficiencies within Africa's regulatory professional community. It will then coordinate comprehensive training programs, mentorship opportunities, peer learning initiatives, and professional attachments to address these gaps. This hub is designed to enhance, rather than duplicate, existing capacity-building efforts supported by various international and regional bodies, including the World Health Organization (WHO), regional economic communities, national regulatory authorities, universities, and technical partners.

Leveraging a collaborative approach, the hub will draw upon the extensive knowledge and experience of African regulatory authorities, particularly those that have achieved Maturity Level 3 under the WHO Global Benchmarking Tool. It will also integrate expertise from Regional Centres of Regulatory Excellence and other established networks, ensuring a robust and continent-wide dissemination of best practices in African pharmaceutical regulation harmonization.

A key component of the new infrastructure is the AMA Regulatory Innovation and Manufacturing Readiness Hub, which aims to engage pharmaceutical manufacturers and innovators at an earlier stage of product development. This proactive engagement involves providing crucial scientific guidance and assisting them in preparing to meet the stringent regulatory requirements for product quality, safety, and efficacy. This initiative directly addresses the practical and legal challenges faced by companies seeking to introduce new medical products in Africa.

Director-General Darko highlighted the imperative for Africa to move beyond being merely a consumer market for medical products developed and produced elsewhere. She asserted that African innovators and manufacturers require an enabling environment characterized by timely scientific advice, clear regulatory expectations, and robust support to help them adhere to the rigorous standards set by regulatory agencies. An illustrative example of this value is AMA's involvement with an Ebola vaccine candidate currently under development and manufacturing in Egypt, showcasing the benefits of early scientific counsel in the product development lifecycle.

The establishment of these African Medicines Agency Kigali regulatory hubs is expected to have profound implications for market access and regulatory efficiency across the continent. Michel Sidibé, the African Union Special Envoy for AMA, noted that these hubs will enable the agency to tap into diverse expertise across Africa, rather than centralizing all operations solely at its Kigali headquarters. This distributed model facilitates regulators in various critical functions, including assessing new medicines, monitoring adverse effects, verifying the bioequivalence of generic drugs, and sharing scientific evaluations and regulatory documentation.

This collaborative framework is poised to significantly reduce redundant efforts and accelerate the approval process for medicines, thereby impacting Rwanda medicine regulatory decisions and those across the continent. Sidibé underscored the current challenge where some molecules face delays of five to six years due to the necessity of navigating 55 distinct national regulatory systems. A more coordinated regulatory system, he added, would also strategically enhance Africa's collective negotiating power when engaging with global pharmaceutical manufacturers and suppliers. Prof Paul Lalvani, founder of the Empower School of Health, further suggested that AMA could effectively partner with existing training institutions and regulatory networks to broaden the reach of this specialized expertise.

Lawyers advising pharmaceutical manufacturers and innovators should inform clients about the new AMA hubs in Kigali, particularly the Regulatory Innovation and Manufacturing Readiness Hub, which offers early scientific guidance to streamline product development and market entry across Africa. Compliance officers should monitor how these hubs facilitate harmonized and accelerated regulatory processes, potentially simplifying market access and compliance strategies for medical products on the continent.

Source: Original reporting via news reports